Jason Butler, an analyst from JMP Securities, reiterated the Buy rating on Vigil Neuroscience Inc (VIGL – Research Report). The associated ...
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 ...
Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.
WATERTOWN, Mass. - Vigil Neuroscience , Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company, has announced the progression of its Alzheimer’s disease (AD) candidate, VG-3927, into a Phase 2 ...
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – – Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback